Summary

  • Enterosgel reduces severity and remission time for peptic duodenal ulcer caused by candida in children.


Abstract

Background: 

To study the clinical endoscopic effectiveness of Enterosgel as a part of standard treatment of Helicobacter pylori (HP) — positive peptic duodenal ulcer (PDU) associated with fungi of the genus Candida in children.

Methods: 

The prospective, controlled, randomized, open, single site study included 55 children aged from 7 to 18 years old with HP-positive PDU associated with Candida fungi. Of them, 30 patients (the main group) received Enterosgel in an age-appropriate dose for 14 days in addition to the standard therapy. In the comparison group, 25 children were subjected exclusively to the standard therapy.

Results: 
In the main group, where patients received Enterosgel additionally to the standard therapy, the overall therapeutic effect was 87% versus 72% in the comparison group. Besides, exacerbations were less severe and their duration was reduced by 28% with complete endoscopic remission on the background of negative results of culture mycological examination of the biopsy specimens of the mucous membrane of the duodenum, and the level of circulating candidiasis antibodies was decreased to trace amounts.
Conclusions: 

The results of the study open up new possibilities for the use of Enterosgel in the treatment of children with HP-positive PDU associated with fungi of the genus Candida.

Source: https://pharmateca.ru/en/archive/article/35982